Cresco Labs Inc. CRLBF
Annual
Quarterly
FY2025 · ended Dec 31, 2025 · Revenue $655.85M, -9.5% YoY · Filed Mar 6, 2026
Cresco Labs Inc. (CRLBF) files with the SEC under industry code 2833, Medicinal Chemicals & Botanical Products. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $655.8 million and a net loss of $135.4 million. Free cash flow was $37.8 million. As of Dec 31, 2025 it held $57.9 million in cash and investments and $612.0 million in total debt.
Revenue
$655.85M
-9.5% vs prior year
Net income
$-135.41M
-81.9% vs prior year
Operating cash flow
$72.89M
-45.0% vs prior year
Free cash flow
$37.75M
-66.6% vs prior year
EPS
$-0.38
-72.7% vs prior year
Dividend per share
None
Shares outstanding
—
Net cash
$-554.07M
FY 2025
Operating margin
-4.3%
FY 2025
Company profile
- Industry
- Medicinal Chemicals & Botanical Products (SIC 2833)
- Listed as
- CRLBF (OTC)
- Fiscal year ends
- December 31
- Incorporated in
- British Columbia, Canada
- Headquarters
- Chicago, IL
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1832928
Other Medicinal Chemicals & Botanical Products companies
- Definium Therapeutics, Inc. DFTX
- Regencell Bioscience Holdings Ltd RGC
- Curaleaf Holdings, Inc. CURLF
- Trulieve Cannabis Corp. TRLV
- Cronos Group Inc. CRON
- TFA Therapeutics, Inc. RAJAF
- Tilray Brands, Inc. TLRY
- SNDL Inc. SNDL
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $655.8M | $724.3M | $770.9M | $842.7M | $821.7M |
| Operating income | -$28.0M | $107.3M | — | — | — |
| Net income | -$135.4M | -$74.4M | — | — | — |
| Diluted EPS | -$0.38 | -$0.22 | — | — | — |
| Operating cash flow | $72.9M | $132.5M | $58.6M | $18.7M | $14.5M |
| Free cash flow | $37.8M | $113.0M | $3.2M | -$64.3M | -$79.4M |
| Total assets | $1.2B | $1.4B | $1.4B | $1.6B | $1.8B |
| Total liabilities | $944.8M | $967.2M | $930.4M | $996.0M | $982.7M |
| Stockholders' equity | $340.4M | $474.9M | — | — | — |
| Cash and investments | $57.9M | $137.6M | $103.4M | $119.3M | $223.5M |
| Total debt | $612.0M | $661.7M | $670.9M | $659.2M | $604.8M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 6-K | Current report (foreign issuer) | Nov 3, 2026 | Nov 2, 2026 |
| 6-K | Current report (foreign issuer) | Oct 13, 2026 | Oct 13, 2026 |
| 6-K | Current report (foreign issuer) | Sep 30, 2026 | Sep 30, 2026 |
| 6-K | Current report (foreign issuer) | Aug 6, 2026 | Jun 30, 2026 |
| 6-K | Current report (foreign issuer) | May 8, 2026 | Mar 31, 2026 |
| 40-F | Annual report (Canadian issuer) | Mar 6, 2026 | Dec 31, 2025 |
All 93 Cresco Labs Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.